SpringWorks Therapeutics General and Administrative Expenses 2011-2026 | SWTX

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses SpringWorks Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
257 M	198 M	135 M	71.8 M	29.5 M	16.7 M	8.59 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
257 M	8.59 M	102 M

Quarterly General and Administrative Expenses SpringWorks Therapeutics

2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
76.5 M	-	61.6 M	57.8 M	60.1 M	-	46.5 M	47 M	44.2 M	-	35.7 M	31 M	27.4 M	-	18 M	14.9 M	12.4 M	-	7.67 M	6.87 M	6.4 M	-	4.58 M	3.65 M	3.26 M	-	1.82 M	-	-	1.86 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
76.5 M	1.82 M	27.1 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
ACADIA Pharmaceuticals ACAD	488 M	$ 22.57	0.04 %	$ 3.74 B	USA
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Akebia Therapeutics AKBA	107 M	$ 1.41	-1.4 %	$ 363 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
BioNTech SE BNTX	286 M	$ 91.98	-0.11 %	$ 27.2 B	Germany
Aytu BioScience AYTU	17.4 M	$ 2.56	-3.76 %	$ 16.1 M	USA
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.85	-1.39 %	$ 9.26 B	Australia
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	85.9 M	$ 20.87	2.3 %	$ 976 M	USA
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
Aquestive Therapeutics AQST	79.8 M	$ 4.17	-0.24 %	$ 446 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Arcutis Biotherapeutics ARQT	275 M	$ 24.57	-0.16 %	$ 3.13 B	USA
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Cabaletta Bio CABA	29.6 M	$ 3.17	2.59 %	$ 319 M	USA
Codiak BioSciences CDAK	27.6 M	-	-55.98 %	$ 2.15 M	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Avid Bioservices CDMO	26 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	20.6 M	-	-	$ 1.41 B	USA
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 2.93	-4.87 %	$ 6.38 B	Israel
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Celldex Therapeutics CLDX	43.8 M	$ 33.62	3.73 %	$ 2.23 B	USA
Concert Pharmaceuticals CNCE	22.5 M	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	9.28 M	$ 3.92	1.03 %	$ 264 B	Britain
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Celsion Corporation CLSN	6.87 M	-	-6.63 %	$ 13.9 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA